

## Celid, "Corona 19 vaccine AdCLD-CoV19, the first clinical trial subject to be administered"

---

Date: 2021.01.05

---

On the 4th, Celid announced on the 5th that the first phase of clinical trial in Korea, 'AdCLD-CoV19', which was developed by itself, was administered to the first test subject at Korea University Guro Hospital.

This clinical trial is planned to be conducted on healthy adult volunteers to explore the safety and immunogenicity of the COVID-19 vaccine 'AdCLD-CoV19', and it is expected to recruit 30 subjects for phase 1 and 120 subjects for phase 2a.

Celid aims to enter phase 2b in the first half of this year after securing intermediate results for initial safety and immunogenicity by conducting clinical phase 1/2a as soon as possible. After that, it plans to promote domestic emergency use based on the safety and immunogenicity results confirmed through phase 2b.

'AdCLD-CoV19' has already produced a high level of neutralizing antibodies that neutralize the virus with only a single (one) administration in the efficacy test for primates, and coronavirus-specific T cells that can remove infected cells are also effective. It was confirmed to activate. In addition, in the subsequent infection defense test, it was confirmed that the live coronavirus was completely killed in the upper respiratory tract (nose, throat) and lung tissue, resulting in meaningful results.

Celid recently signed a business cooperation agreement with Korea University Guro Hospital to conduct clinical trials, and signed a research service contract with the International Vaccine Research Institute (IVI) to analyze samples for clinical trials. Efforts are being made to achieve the target for domestic use.

---